Media stories about Syndax Pharmaceuticals (NASDAQ:SNDX) have been trending somewhat positive recently, according to Accern. The research firm identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Syndax Pharmaceuticals earned a news impact score of 0.16 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 46.2215349356018 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Here are some of the headlines that may have effected Accern Sentiment’s rankings:

Shares of Syndax Pharmaceuticals (NASDAQ:SNDX) traded up $0.09 during mid-day trading on Monday, hitting $10.11. 167,200 shares of the stock were exchanged, compared to its average volume of 113,041. Syndax Pharmaceuticals has a twelve month low of $6.31 and a twelve month high of $15.70.

Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its quarterly earnings data on Tuesday, November 7th. The company reported ($0.68) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.80) by $0.12. The business had revenue of $0.31 million for the quarter, compared to analyst estimates of $0.30 million. Syndax Pharmaceuticals had a negative net margin of 4,304.34% and a negative return on equity of 57.90%. The firm’s revenue for the quarter was up .0% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.84) earnings per share. research analysts forecast that Syndax Pharmaceuticals will post -3.1 EPS for the current year.

A number of research analysts have weighed in on SNDX shares. Zacks Investment Research raised shares of Syndax Pharmaceuticals from a “hold” rating to a “buy” rating and set a $15.00 price target on the stock in a research note on Tuesday, July 18th. ValuEngine lowered shares of Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, July 17th. Instinet reaffirmed a “buy” rating and issued a $22.00 price target (down previously from $27.00) on shares of Syndax Pharmaceuticals in a research note on Monday, August 14th. Citigroup Inc. set a $20.00 price target on shares of Syndax Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, August 11th. Finally, Nomura cut their price target on shares of Syndax Pharmaceuticals from $27.00 to $22.00 and set a “buy” rating on the stock in a research note on Friday, August 11th. Two research analysts have rated the stock with a sell rating and eight have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $23.13.

TRADEMARK VIOLATION WARNING: “Syndax Pharmaceuticals (SNDX) Given News Sentiment Rating of 0.16” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright law. The correct version of this piece can be viewed at

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer.

Insider Buying and Selling by Quarter for Syndax Pharmaceuticals (NASDAQ:SNDX)

Receive News & Stock Ratings for Syndax Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.